Tradename | Company | Number | Date | Products |
---|---|---|---|---|
KORLYM | Corcept Therapeutics | N-202107 RX | 2012-02-17 | 1 products, RLD, RS |
MIFEPREX | Danco Laboratories | N-020687 RX | 2000-09-28 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
korlym | New Drug Application | 2025-01-21 |
mifeprex | New Drug Application | 2025-03-12 |
mifepristone | New Drug Application | 2025-01-28 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
brain neoplasms | EFO_0003833 | D001932 | C71 |
meningeal neoplasms | EFO_0003851 | D008577 | C70 |
hyperglycemia | — | D006943 | R73.9 |
ectopic pregnancy | — | D011271 | O00 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Mifepristone, Korlym, Corcept Therap | |||
10231983 | 2038-08-22 | U-1643 | |
10314850 | 2038-08-22 | U-1643 | |
10780097 | 2038-08-22 | U-1643 | |
10195214 | 2037-06-19 | U-1643 | |
10842800 | 2037-06-19 | U-1643 | |
10151763 | 2037-01-18 | U-1643 | |
9829495 | 2036-08-15 | U-1643 | |
10006924 | 2036-08-12 | U-1643 | |
10495650 | 2036-08-12 | U-1643 | |
9943526 | 2036-04-20 | U-1643 | |
10166242 | 2036-04-20 | U-1643 | |
10166243 | 2036-04-20 | U-1643 | |
10660904 | 2036-04-20 | U-1643 | |
10500216 | 2033-03-05 | U-1643 | |
10842801 | 2032-11-15 | U-1643 | |
8921348 | 2028-08-27 | U-1643 |
Code | Description |
---|---|
S0190 | Mifepristone, oral, 200 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | 3 | 1 | 2 | 6 |
Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | — | — | — | 1 | 1 | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 6 | — | — | 7 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 6 | — | — | 7 |
Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | 4 | — | 2 | 6 |
Psychotic disorders | D011618 | — | F20.81 | — | — | 6 | — | — | 6 |
Depression | D003863 | — | F33.9 | — | — | 6 | — | — | 6 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 6 | — | — | 6 |
Syndrome | D013577 | — | — | — | — | 3 | — | 2 | 5 |
Acth-secreting pituitary adenoma | D049913 | — | — | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 2 |
Weight gain | D015430 | — | — | 1 | 1 | — | — | — | 2 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | — | 1 |
Adrenal insufficiency | D000309 | — | — | — | 1 | — | — | — | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Mifepristone |
INN | mifepristone |
Description | Mifepristone is a 3-oxo-Delta(4) steroid, an acetylenic compound and a tertiary amino compound. It has a role as an abortifacient, a contraceptive drug, a synthetic oral contraceptive and a hormone antagonist. It derives from a hydride of an estrane. |
Classification | Small molecule |
Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); progesterone receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C |
PDB | — |
CAS-ID | 84371-65-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1276308 |
ChEBI ID | 50692 |
PubChem CID | 55245 |
DrugBank | DB00834 |
UNII ID | 320T6RNW1F (ChemIDplus, GSRS) |